ArticleJournal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology2026
Epithelial-Mesenchymal Transition, Immune Response, and Extracellular Matrix Remodelling in Oral Cancer.
Article in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Remodeling mechanisms and intervention strategies of the oral mucosal immune barrier.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimThis retrospective study investigates the interplay between epithelial-mesenchymal transition (EMT) and immune response within the tumor microenvironment (TME) of oral squamous cell carcinoma (OSCC). METHODOLOGY: Immunohistochemistry was conducted on OSCC specimens to evaluate the expression of podoplanin (PDP), E-cadherin (CDH1), vimentin (VIM), fibronectin (FN), tenascin-C (TNC), and vascular endothelial growth factor (VEGF). Cancer-associated fibroblasts (CAFs) were identified by alpha-smooth muscle actin (α-SMA), and immune cells were quantified using CD66b for neutrophils and CD8 for T lymphocytes.
resultsHigher α-SMA and moderate-to-strong VEGF expression were associated with reduced CDH1 and increased VIM and PDP expression (p < 0.05), indicating an EMT-like phenotype. Cases with elevated PDP-also linked to high α-SMA-showed increased CD66b
conclusionThese exploratory findings suggest that CAFs serve not only as a marker of stromal activation but may also contribute to immunomodulation and invasive tumor phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.